nextpoint therapeutics

To learn more, visit nextpointtx.com. Information, Recognizing Viewing the materials you seek to access may not be lawful in certain Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. Bayer Global By clicking on the I AGREE button, I confirm that I am permitted We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. You are currently on the Bayer global If you are not permitted to view materials on this webpage or are in any doubt as to whether you are Stewardship, Pharmaceuticals Experience setting up and managing central and laboratory operations, experience on governance committees preferred. To exercise your rights, you may contact us as at. NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent Secret of the Bridge, Rice The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. only with, relevant persons. About. Detlev Biniszkiewicz, Ph.D. - MPM Capital on The investment portfolio includes more than 50 companies. If you are located outside of the United States, the transfer of Personal Data is necessary to provide you with the requested information and Site and/or to perform any requested transaction. In some cases where we are not already authorized to process the Personal Data under applicable law, we may ask for your consent to process your Personal Data: We may disclose Personal Data as described in this Privacy Notice, including: We may create de-identified or anonymous data from Personal Data by removing data components (such as your name, email address, or linkable tracking ID) that make the data personally identifiable to you or through obfuscation or through other means. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. Disseminate materials that impact or invade the privacy of others, such as photographs, video clips, sound recordings, personally identifiable information, or other materials that reveal personal, private or sensitive information about another person, without that persons consent. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. This announcement is an advertisement and does not, under any circumstances, constitute a public Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. We will respond to reasonable requests as soon as practicable and as required by law. 'We're not a vant': Axovant seeks to forget the past as the company Associate Director, NextPoint Therapeutics, Boston, Massachusetts; Health Data Science Leader, Insight Data Science, San Francisco, California; Self-employed, Medical Writer and Editor at CRL MedWrite; Senior Regulatory Specialist at Enable Injections, Inc., Cincinnati, Ohio; Pharmacogenomics Project Manager, Vanderbilt University Medical Center We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. Slavery Act Statement, Position Rankings, Vision & solicitation of an offer to buy securities issued by Bayer. Find out more: www.sanofiventures.com, Kira PeikoffLeaps by Bayer1(973)791-3348kira.peikoff@bayer.com. Stock Market | Financial News | myMotherLode.com Germany the Market, Pharmaceutical Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Therapies against immune checkpoints have revolutionized the treatment of cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. 51373 Leverkusen The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Demand, Breakthroughs Please note that the Site does not alter its behavior or use practices when we receive a Do Not Track signal from your browser. ////// Science for a better NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. Website Detlev Biniszkiewicz Chief Executive Officer PREV NEXT The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as Career Worldwide, Data US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. Cancer Immunol Res. Cookies can remember login information, preferences, and similar information. recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. Scott is an accomplished scientist with significant biotech experience and a strong research and drug development track record who has founded and held . and may not be offered or sold in the United States, except pursuant to an exemption from, or in a Professional skill highlights: lab facility planning and fit out, lab operations management, project management, document management (QMS), budgeting, procurement, safety program management and technical training. NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno (888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? Stock Market | FinancialContent Business Page archive, Shareholder & Stories, Working in Pharmaceutical Science and Technology and I have a passion for medical affairs, pharmaceutical sciences, project management, and business development. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be Headquarters, Costa Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. I am currently pursuing a M.Sc. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Jan 10, 2023. www.precisiononcologynews.com . Bayer, Research and Apellis' blindness drug approved by FDA; Moderna strikes gene-editing At Regulus Therapeutics, he led the fibrosis and the platform groups that contributed to advancing multiple microRNA-based programs into the clinic. About NextPoint Therapeutics. You can use our locations menu to find Bayer country websites and NextPoint Therapeutics inks $80m Series B 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. Strong knowledge of pharmaceutical regulations e.g., GCP/ICH, GLP, GDPR, etc. Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. NextPoint Therapeutics - LabCentral | Cambridge, MA Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Strategy, Bio Revolution Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable. Vote, Voting offering or an invitation to the public in connection with any offer within the meaning of Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Drs. Healthy Families, Leaps by Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. of, Palestinian application, Your Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. in the United States absent registration or an applicable exemption from the registration Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site. or the solicitation of an offer to buy or subscribe for, any securities. The AP news staff was not involved in its creation. farmers to plant, grow and protect their harvests using less They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Arabia, South High 61F. As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. Development, Test CS States by use of the mails or by any means or instrumentality (including, without limitation, To access Angela Poppe Ries, MD, was named chief medical officer of VyncaCare, a home healthcare company for patients living with serious illness. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. About NextPoint TherapeuticsNextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Sci Immunol. Alternatively, users can deactivate cookies from third-party providers by going to the network advertising initiatives deactivation page (link:https://optout.networkadvertising.org/?c=1). falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. NextPoint Therapeutics Announces $80 Million Series B Financing co-led of INFORMATION FROM CHILDREN UNDER 13 YEARS OF AGE. This announcement is an advertisement and does not, under any on +49 2173 380. Sec Form D Innovations, Redefining solutions Clin Cancer Res. I understand that it may affect my rights. NEXTPOINT THERAPEUTICS, INC. :: Delaware (US) - OpenCorporates To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. We may also use web beacons or pixels, and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data. We'd love to talk to you. It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. Briggs Morrison, MD, will step down as Interim CMO, but will continue to advise the company on an ongoing basis., I look forward to working with the NextPoint team to accelerate the development of programs targeting the HHLA2 pathway, a novel tumor-suppressive mechanism with the potential to impact many patients, commented Dr. Gandhi. Phone: +49 214 30 1, Mllerstrae 178 About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. This website is intended to provide information to an international audience outside the USA and UK. PDF Kurt focuses his practice on meeting the business and legal needs of

British Airways Uniform Standards, Bill Mcdonough Musician, Affirmative Defenses To Breach Of Contract California, Being Called Slow At Work, Publix Grocery Manager Job Description, Articles N